ArticleEClinicalMedicine2026
Efficacy and safety of AAV-mediated gene therapy for choroideremia: a systematic review and meta-analysis.
Article in EClinicalMedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Choroideremia is a rare X-linked inherited retinal dystrophy caused by mutations in the Methods: A systematic review and meta-analysis were conducted in accordance with Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) 2020 guidelines and registered in International Prospective Register of Systematic Reviews (PROSPERO) (CRD420251146173). Six databases (PubMed, Embase, Scopus, ScienceDirect, Web of Science, and the Cochrane Library) were searched from inception to December 3, 2025. Clinical trials and prospective observational studies evaluating AAV-mediated gene therapy targeting the Rab escort protein 1 (REP1) gene were included. Outcomes included best-corrected visual acuity (BCVA), retinal sensitivity measured by microperimetry, preserved RPE area on fundus autofluorescence (FAF), subfoveal choroidal thickness, and treatment-emergent adverse events (TEAEs). Random-effects meta-analyses were performed using Comprehensive Meta-Analysis software. Findings: Eleven clinical studies involving 308 participants were included. Gene therapy demonstrated a significant improvement in retinal sensitivity (mean difference [MD] 0.78 dB, 95% CI: 0.58-0.99, p < 0.001) with consistent effects across follow-up durations up to 48 months. BCVA showed a significant pooled improvement of 3.07 Early Treatment Diabetic Retinopathy Study (ETDRS) letters (95% CI: 1.85-4.30, p < 0.001), with greater gains observed at 24 months. Structural outcomes indicated reduced RPE degeneration (MD -4.41, 95% CI: -6.39 to -2.44, p < 0.001) and increased subfoveal choroidal thickness (MD 9.13 μm, 95% CI: 7.53-10.72, p < 0.001). TEAEs occurred in approximately 35% of treated participants in the pooled event-rate analysis, with the majority of events being mild to moderate and procedure-related, and a relatively low incidence of serious adverse events (<20%). Interpretation: AAV-mediated gene therapy for choroideremia demonstrates modest functional benefits and structural preservation signals. TEAEs are relatively common and are predominantly procedure-associated ocular events, although most reported events are mild to moderate and serious complications remain uncommon. The therapy appears to act primarily as a disease-modifying intervention that stabilizes retinal degeneration rather than restoring vision, supporting further trials with earlier intervention, optimized delivery strategies, and longer follow-up. Funding: No specific funding was received from any funding bodies in the public, commercial, or not-for-profit sectors.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.